Treatment with JX5 in T-ALL can produce effects similar to knocking out IGF2BP2, inhibiting the proliferation of T-ALL cells and prolonging animal survival [117]. The gene discussed is IGF2BP2; the disease is acute lymphoblastic leukemia.